Antisense inhibition of macrophage inflammatory protein 1-α blocks bone destruction in a model of myeloma bone disease

被引:132
作者
Choi, SJ
Oba, Y
Gazitt, Y
Alsina, M
Cruz, J
Anderson, J
Roodman, GD
机构
[1] Univ Texas, Hlth Sci Ctr, Dept Med Hematol, San Antonio, TX USA
[2] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA
[3] Texas Tech Univ, Hlth Sci Ctr, Lubbock, TX 79430 USA
[4] Audie L Murphy Mem Vet Adm Med Ctr, San Antonio, TX 78284 USA
关键词
D O I
10.1172/JCI13116
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
We recently identified macrophage inflammatory protein 1-alpha (MIP-1 alpha) as a factor produced by multiple myeloma (MM) cells that maybe responsible for the bone destruction in MM (1). To investigate the role of MIP-1 alpha in MM bone disease in vivo, the human MM-derived cell line ARH was stably transfected with an antisense construct to MIP-1 alpha (AS-ARH) and tested for its capacity to induce MM bone disease in SCID mice. Human MIP-1 alpha levels in marrow plasma from AS-ARH mice were markedly decreased compared with controls treated with ARH cells transfected with empty vector (EV-ARH). Mice treated with AS-ARH cells lived longer than controls and, unlike the controls, they showed no radiologically identifiable lytic lesions. Histomorphometric analysis demonstrated that osteoclasts (OCLs) per square millimeter of bone and OCLs per millimeter of bone surface of AS-ARH mice were significantly less than in EV-ARH mice, and the percentage of tumors per total bone area was also significantly decreased. AS-ARH cells demonstrated decreased adherence to marrow stromal cells, due to reduced expression of the alpha (5)beta (1) integrin and diminished homing capacity and survival. These data support an important role for MIP-1 alpha in cell homing, survival, and bone destruction in MM.
引用
收藏
页码:1833 / 1841
页数:9
相关论文
共 22 条
  • [1] Development of an in vivo model of human multiple myeloma bone disease
    Alsina, M
    Boyce, B
    Devlin, RD
    Anderson, JL
    Craig, F
    Mundy, GR
    Roodman, GD
    [J]. BLOOD, 1996, 87 (04) : 1495 - 1501
  • [2] Barlogie B, 1997, CLIN CANCER RES, V3, P2605
  • [3] Cloning and identification of human sea as a novel inhibitor of osteoclast formation and bone resorption
    Choi, SJ
    Devlin, RD
    Menaa, C
    Chung, H
    Roodman, GD
    Reddy, SV
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1998, 102 (07) : 1360 - 1368
  • [4] Choi SJ, 2000, BLOOD, V96, P671
  • [5] Cell adhesion mediated drug resistance (CAM-DR): Role of integrins and resistance to apoptosis in human myeloma cell lines
    Damiano, JS
    Cress, AE
    Hazlehurst, LA
    Shtil, AA
    Dalton, WS
    [J]. BLOOD, 1999, 93 (05) : 1658 - 1667
  • [6] CHEMOKINES REGULATE CELLULAR-POLARIZATION AND ADHESION RECEPTOR REDISTRIBUTION DURING LYMPHOCYTE INTERACTION WITH ENDOTHELIUM AND EXTRACELLULAR-MATRIX - INVOLVEMENT OF CAMP SIGNALING PATHWAY
    DELPOZO, MA
    SANCHEZMATEOS, P
    NIETO, M
    SANCHEZMADRID, F
    [J]. JOURNAL OF CELL BIOLOGY, 1995, 131 (02) : 495 - 508
  • [7] FULLER K, 1995, J IMMUNOL, V154, P6065
  • [8] Expression of adhesion molecules on CD34+ cells in peripheral blood of non-Hodgkin's lymphoma patients mobilized with different growth factors
    Gazitt, Y
    Shaughnessy, P
    Liu, Q
    [J]. STEM CELLS, 2001, 19 (02) : 134 - 143
  • [9] Macrophage inflammatory protein-1α is an osteoclastogenic factor in myeloma that is independent of receptor activator of nuclear factor κB ligand
    Han, JH
    Choi, SJ
    Kurihara, N
    Koide, M
    Oba, Y
    Roodman, GD
    [J]. BLOOD, 2001, 97 (11) : 3349 - 3353
  • [10] Adhesion to fibronectin via β1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR)
    Hazlehurst, LA
    Damiano, JS
    Buyuksal, I
    Pledger, WJ
    Dalton, WS
    [J]. ONCOGENE, 2000, 19 (38) : 4319 - 4327